Party time!!!!!!!!!!

In celebration of the approval of Spinraza the Annabelle Rose Foundation organised a party called the Cirque du Spinraza where many of the community attended on Saturday.

Aswel as the life that SMA gives us with appointments, fittings, physio, hospital stays and many many battles to get what our children and ourselves deserve we all have the pandemonium of everyday life on top with school, jobs, sibblings, relationships, bills etc.

Through all the chaos and the ups and downs, the only constant that runs through our veins that never changes or disappoints is our community, the SMA community. The heart beat. The friendships that pick you up, understand, help and more recently worked together uniting to fight for treatment for ALL.

On Saturday ‘The Annabelle Rose Foundation’ held a party to celebrate the success with Spinraza. Even though we are all still fighting for others, it was important that after two and half years of the community working tirelessly that we acknowledge and celebrated all of our work so far.

Thank you Charlotte, Wayne and helpers for an amazing day and night. Here is a video of a collection of memories from a beautiful day.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more